Established in June 2018, Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases.
The Executive Director, Intellectual Property & Legal will lead and elevate the company's global IP strategy, serving as the senior IP authority and a key member of the legal leadership team.
Established in June 2018, Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases.
Celestica